Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide.
Saviola
Alessia
A
Luppi
Mario
M
Potenza
Leonardo
L
Morselli
Monica
M
Ferrari
Angela
A
Riva
Giovanni
G
Torelli
Giuseppe
G
D000208:Acute Disease; D000368:Aged; D000617:Aminoglycosides / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D000079982:Gemtuzumab; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D013997:Time Factors
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D000079982:Gemtuzumab